Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries

Proposed growth factor explanation of cerebral vasospasm

Zhi Wen Zhang, Hiroji Yanamoto, Izumi Nagata, Susumu Miyamoto, Yukako Nakajo, Jing Hui Xue, Koji Iihara, Haruhiko Kikuchi

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

Original languageEnglish
Pages (from-to)728-735
Number of pages8
JournalNeurosurgery
Volume66
Issue number4
DOIs
Publication statusPublished - Apr 1 2010

Fingerprint

Intracranial Vasospasm
Cerebral Arteries
Trapidil
Platelet-Derived Growth Factor
Vasoconstriction
Intercellular Signaling Peptides and Proteins
Subarachnoid Hemorrhage
Subarachnoid Space
Basilar Artery
platelet-derived growth factor BB
Constriction
Intravenous Administration
Half-Life
Angiography
Arteries
Rabbits

All Science Journal Classification (ASJC) codes

  • Surgery
  • Clinical Neurology

Cite this

Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries : Proposed growth factor explanation of cerebral vasospasm. / Zhang, Zhi Wen; Yanamoto, Hiroji; Nagata, Izumi; Miyamoto, Susumu; Nakajo, Yukako; Xue, Jing Hui; Iihara, Koji; Kikuchi, Haruhiko.

In: Neurosurgery, Vol. 66, No. 4, 01.04.2010, p. 728-735.

Research output: Contribution to journalArticle

Zhang, Zhi Wen ; Yanamoto, Hiroji ; Nagata, Izumi ; Miyamoto, Susumu ; Nakajo, Yukako ; Xue, Jing Hui ; Iihara, Koji ; Kikuchi, Haruhiko. / Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries : Proposed growth factor explanation of cerebral vasospasm. In: Neurosurgery. 2010 ; Vol. 66, No. 4. pp. 728-735.
@article{f09a59696f7441c7abc80e5d41c49f13,
title = "Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: Proposed growth factor explanation of cerebral vasospasm",
abstract = "OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56{\%} (P < .001) of the control value (= 100{\%}) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.",
author = "Zhang, {Zhi Wen} and Hiroji Yanamoto and Izumi Nagata and Susumu Miyamoto and Yukako Nakajo and Xue, {Jing Hui} and Koji Iihara and Haruhiko Kikuchi",
year = "2010",
month = "4",
day = "1",
doi = "10.1227/01.NEU.0000366111.08024.26",
language = "English",
volume = "66",
pages = "728--735",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries

T2 - Proposed growth factor explanation of cerebral vasospasm

AU - Zhang, Zhi Wen

AU - Yanamoto, Hiroji

AU - Nagata, Izumi

AU - Miyamoto, Susumu

AU - Nakajo, Yukako

AU - Xue, Jing Hui

AU - Iihara, Koji

AU - Kikuchi, Haruhiko

PY - 2010/4/1

Y1 - 2010/4/1

N2 - OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

AB - OBJECTIVE: After subarachnoid hemorrhage (SAH), platelet-derived growth factor-BB (PDGF-BB) is secreted in and around the cerebral arteries. To clarify the role of PDGF-BB in the development of vasospasm after SAH, we determined whether PDGF-BB alone can cause long-lasting vasoconstriction of a severity similar to that of vasospasm. In addition, the anti-vasospastic effect of trapidil, an antagonist of PDGF-BB function, was investigated. METHODS: We infused recombinant PDGF-BB (10 μg/mL saline as the vehicle) (n = 14) into the subarachnoid space of rabbits and analyzed alterations in the caliber of the basilar artery using repeated angiography. To study the role of PDGF-BB on the development of vasospasm, trapidil was administered continuously starting 1 hour after SAH, on day 0 (0.63-1.25 mg/kg /h or vehicle) for 47 hours (n = 24), or after the full development of cerebral vasospasm on day 2 (3.0 mg/kg/h or vehicle) for 0.5 hours (n = 17), and alterations in the caliber of the basilar artery were monitored. RESULTS: PDGF-BB caused long-lasting vasoconstriction, with maximum constriction of 56% (P < .001) of the control value (= 100%) on day 2, resembling vasospasm seen after SAH. Prolonged administration of intravenous trapidil, starting soon after SAH, prevented the development of vasospasm in a dose-dependent manner (P < .05, .01, or .001). Intravenous or intra-arterial administration of trapidil significantly dilated vasospasm (P < .01) on day 2, at least transiently. CONCLUSION: PDGF-BB, a growth factor synthesized in the subarachnoid space after SAH, can cause severe and long-lasting vasoconstriction. Significant prevention and resolution of vasospasm can be achieved by the PDGF-BB antagonist trapidil. We propose that excessive production of PDGF-BB, essentially aiming to repair injured arteries, causes cerebral vasospasm. Although the half-life of trapidil in serum may be shorter than that of PDGFG-BB-derived spasmogenic signaling, trapidil is a candidate drug for constructing a new therapeutic modality for preventing and resolving vasospasm.

UR - http://www.scopus.com/inward/record.url?scp=77949976466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949976466&partnerID=8YFLogxK

U2 - 10.1227/01.NEU.0000366111.08024.26

DO - 10.1227/01.NEU.0000366111.08024.26

M3 - Article

VL - 66

SP - 728

EP - 735

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

IS - 4

ER -